KRAS activating mutations are widely recognised as predictors of resistance to the treatment with anti-EGFR monoclonal antibodies (moAbs) in metastatic colorectal cancer (mCRC) patients [6, 7]. The gene discussed is EGFR; the disease is metastatic colorectal cancer.